---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-020177"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2022-05-23T23:59:59+00:00"
generated_at: "2026-06-25T08:04:19.961205+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Insmed appoints Drayton Wise as Chief Commercial Officer; $500k salary, $2.1M equity award

## Summary
- Drayton Wise appointed CCO effective May 23, 2022; previously SVP Head of US & GM of ARIKAYCE.
- Annual base salary of $500,000; target bonus 40% of base; RSU and option award valued at $2.1M.
- RSUs vest 25% per year over four years; options vest 25% on first anniversary then 12.5% semiannually.
- Wise to lead all global commercial functions and join Executive Committee; CEO cites brensocatib launch prep.

## SEC filing metadata
- accession: 0001140361-22-020177
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2022-05-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036122020177/0001140361-22-020177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036122020177/brhc10037965_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-020177
- JSON: https://secwatch.observer/filing/0001140361-22-020177.json
- Plain text: https://secwatch.observer/filing/0001140361-22-020177.txt

## Key facts
- Executive change
  Drayton Wise was appointed as Chief Commercial Officer at INSMED Inc.
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: On May 23, 2022, Insmed Incorporated (the “Company”) announced that Mr. Drayton Wise has been appointed as Chief Commercial Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1104506/000114036122020177/0001140361-22-020177-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.